Salomaa Eija-Riitta, Sällinen Susanna, Hiekkanen Heikki, Liippo Kari
Department of Respiratory Diseases, Turku University Hospital, Alvar Aallon tie 275, FIN-21540 Preitilä, Finland.
Chest. 2005 Oct;128(4):2282-8. doi: 10.1378/chest.128.4.2282.
This study was undertaken to measure delays of diagnosis and to assess the causes for those delays in patients with lung cancer. In addition, the relation of delay times and survival was analyzed.
A retrospective study based on patient records. Dates for symptoms, visits to doctors, investigations, treatment, and death were recorded.
Patients who were found to have lung cancer at Turku University Hospital, Finland, during 2001.
Records of 132 patients were reexamined.
The median delay in patient presentation from first symptoms to first appointment with a general practitioner (GP) was 14 days. The median delay by the GP before writing a referral was 16 days, the median referral delay was 8 days, the median delay from the first visit to a specialist until the diagnosis was 15 days, and the median treatment delay was also 15 days. Thirty percent of patients received treatment within 1 month from the first hospital visit, and 61% received treatment within 2 months. The median symptom-to-treatment delay was almost 4 months. The delay in seeing a specialist was shorter in patients with advanced cancer and small cell lung cancer. About half of our patients fulfilled the criteria of the British Thoracic Society recommendations. A longer specialist treatment delay seemed to correlate with better survival in advanced disease, but it was not an independent significant factor for survival.
Several reasons for long delays were found, but on many occasions patients underwent numerous consecutive procedures before a diagnosis of cancer was confirmed. Shortening the diagnostic and treatment delay times might be possible with little extra cost by a multidisciplinary team approach and by rapid access to carefully planned investigations, but decreasing the patient delay might be more difficult. This study shows that long specialist treatment delays are not correlated with worse prognosis in patients with advanced disease. In patients with more limited disease, the delay time may be more critical, and if curative treatment is the goal, the diagnostic process should proceed without needless delay to avoid a situation in which curable disease becomes incurable.
本研究旨在测量肺癌患者的诊断延迟情况,并评估导致这些延迟的原因。此外,还分析了延迟时间与生存率的关系。
基于患者记录的回顾性研究。记录症状出现日期、就诊日期、检查日期、治疗日期和死亡日期。
2001年期间在芬兰图尔库大学医院被诊断为肺癌的患者。
重新检查了132例患者的记录。
从首次出现症状到首次预约全科医生(GP)的患者就诊中位延迟时间为14天。全科医生在开具转诊单之前的中位延迟时间为16天,中位转诊延迟时间为8天,从首次就诊专科医生到确诊的中位延迟时间为15天,中位治疗延迟时间也为15天。30%的患者在首次就诊医院后的1个月内接受了治疗,61%的患者在2个月内接受了治疗。从出现症状到接受治疗的中位延迟时间接近4个月。晚期癌症和小细胞肺癌患者看专科医生的延迟时间较短。约一半的患者符合英国胸科学会建议的标准。在晚期疾病中,较长的专科治疗延迟似乎与较好的生存率相关,但它并非生存的独立显著因素。
发现了导致长时间延迟的几个原因,但在许多情况下,患者在确诊癌症之前要接受多次连续的检查。通过多学科团队方法以及快速进行精心规划的检查,可能只需很少的额外费用就能缩短诊断和治疗延迟时间,但减少患者延迟可能更困难。本研究表明,在晚期疾病患者中,较长的专科治疗延迟与较差的预后无关。在疾病范围较有限的患者中,延迟时间可能更为关键,如果以治愈性治疗为目标,诊断过程应毫不拖延地进行,以避免可治愈疾病变为不可治愈的情况。